DRG Market Assessment reports

Myelodysplastic syndromes (MDS) are a heterogeneous collection of hematopoietic stem cell disorders, which result in cytopenia and an increased risk of progression to acute myeloid leukemia (AML)…

Clarivate Epidemiology’s coverage of idiopathic pulmonary fibrosis (IPF) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and…

Clarivate Epidemiology’s coverage of idiopathic pulmonary fibrosis (IPF) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and…

Clarivate Epidemiology’s coverage of idiopathic pulmonary fibrosis (IPF) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and…

Clarivate Epidemiology’s coverage of idiopathic pulmonary fibrosis (IPF) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and…

Clarivate Epidemiology’s coverage of idiopathic pulmonary fibrosis (IPF) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and…

Clarivate Epidemiology’s coverage of idiopathic pulmonary fibrosis (IPF) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the diagnosed…

Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key idiopathic pulmonary fibrosis (IPF) patient populations, covering…

Clarivate Epidemiology’s coverage of eosinophilic esophagitis (EoE) comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United States…

Primary membranous nephropathy (pMN), the most common type of MN, is a rare autoantibody-mediated autoimmune kidney disease. Despite being one of the leading causes of nephrotic syndrome in…

Clarivate Epidemiology’s coverage of idiopathic pulmonary fibrosis (IPF) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and…

The PsA therapy market is undergoing significant transformation with the emergence of new treatment options, intensifying competition for favorable payer coverage. TNF-α inhibitors, such as AbbVie…